ESLA

Estrella Immunopharma, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.47
52-Week Range: $0.43 – $3.15
Market Cap: $19.57M
P/E (TTM): —
EPS (TTM): -0.25
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -251.86%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.20
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-6.79M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $20.21M

ESLA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.39M	$10.45M	$4.11M	$10.25M
Selling, General & Admin	$296.25K	$663.19K	$3.20M	$2.81M
Operating Expenses	$1.69M	$11.11M	$7.31M	$13.06M
Operating Income	-$1.69M	-$11.11M	-$7.31M	-$13.06M
EBITDA	-$1.69M	-$11.11M	-$7.31M	-$13.06M
Pretax Income	-$1.69M	-$11.11M	-$7.31M	-$13.06M
Income Tax	$0.00	$0.00	$1.63K	$838.00
Net Income	-$1.69M	-$11.11M	-$7.31M	-$13.06M
Diluted EPS	-0.05	-0.32	-0.27	-0.35
Diluted Shares	35.20M	35.20M	27.10M	36.82M

ESLA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$4.09M	$2.48M	$4.17M	$1.38M
Receivables	—	$273.07K	$288.76K	$292.67K
Current Assets	$4.92M	$2.75M	$4.45M	$1.68M
Total Assets	$4.92M	$3.03M	$4.45M	$3.18M
Current Liabilities	$946.68K	$9.76M	$180.70K	$13.54M
Total Liabilities	$5.96M	$14.77M	$180.70K	$13.54M
Retained Earnings	-$1.07M	-$12.19M	-$19.50M	-$36.99M
Shareholders' Equity	-$1.04M	-$11.74M	$4.27M	-$10.37M
Working Capital	$3.97M	-$7.01M	$4.27M	-$11.87M

ESLA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$1.44M	-$1.34M	-$16.07M	-$1.79M
Free Cash Flow	-$1.44M	-$1.34M	-$16.07M	-$1.79M
Stock-Based Compensation	$129.97K	$409.60K	$1.19M	$618.97K
Investing Cash Flow	$0.00	-$273.07K	$4.96M	—
Financing Cash Flow	$5.53M	$0.00	$12.79M	$2.25M
Share Repurchases	—	$0.00	-$354.44K	-$29.46K
Net Change in Cash	—	-$1.61M	$1.69M	$467.39K

ESLA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.41M	$4.66M	$4.15M	$25.41K	$1.40M	$1.40M
Selling, General & Admin	$694.11K	$883.73K	$648.51K	$587.78K	$891.79K	$684.01K
Operating Expenses	$2.10M	$5.54M	$4.80M	$613.20K	$2.29M	$2.08M
Operating Income	-$2.10M	-$5.54M	-$4.80M	-$613.20K	-$2.29M	-$2.08M
EBITDA	-$2.10M	-$5.54M	-$4.80M	-$613.20K	-$2.29M	-$2.08M
Pretax Income	-$2.10M	-$5.54M	-$4.80M	-$613.20K	-$2.29M	-$2.31M
Income Tax	$13.00	$850.00	$0.00	-$25.00	$0.00	$0.00
Net Income	-$2.10M	-$5.54M	-$4.80M	-$613.17K	-$2.29M	-$2.31M
Diluted EPS	-0.06	-0.15	-0.13	—	-0.05	-0.05
Diluted Shares	36.19M	36.17M	37.10M	—	42.12M	43.00M

ESLA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$421.47K	$1.32M	$1.63M	$1.38M	$1.93M	$146.67K
Receivables	$522.79K	$163.93K	$396.90K	$292.67K	$229.79K	$178.01K
Current Assets	$944.27K	$1.48M	$2.02M	$1.68M	$2.16M	$1.82M
Total Assets	$2.44M	$2.98M	$3.52M	$3.18M	$3.66M	$1.82M
Current Liabilities	$4.28M	$9.08M	$13.36M	$13.54M	$8.93M	$9.26M
Total Liabilities	$4.28M	$9.08M	$13.36M	$13.54M	$8.93M	$9.26M
Retained Earnings	-$26.03M	-$31.58M	-$36.38M	-$36.99M	-$39.28M	-$41.59M
Shareholders' Equity	-$1.83M	-$6.09M	-$9.84M	-$10.37M	-$5.27M	-$7.43M
Working Capital	-$3.33M	-$7.59M	-$11.34M	-$11.87M	-$6.77M	-$7.43M

ESLA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$465.98K	-$414.88K	-$727.33K	-$177.49K	-$6.70M	-$1.78M
Free Cash Flow	-$465.98K	-$414.88K	-$727.33K	-$177.49K	-$6.70M	-$1.78M
Stock-Based Compensation	$159.09K	$159.10K	$152.42K	$148.36K	$146.71K	$145.30K
Financing Cash Flow	-$29.46K	$1.31M	$1.04M	-$64.82K	$7.24M	$4.00
Share Repurchases	-$29.46K	$0.00	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	-$495.44K	$895.12K	$310.02K	-$242.31K	$543.10K	-$1.78M

Market Snapshot

About

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapy treatments for cancer patients. The company's pipeline includes novel therapeutic approaches targeting tumor microenvironments and immune checkpoint pathways to enhance the body's natural cancer-fighting capabilities. Estrella conducts clinical trials to evaluate the safety and efficacy of its investigational drugs across multiple cancer indications. The company collaborates with research institutions and clinical centers to advance its development programs toward regulatory approval.